Post de Consulat général de France à Boston

Alzinova ABs Business Development Director Sebastian Hansson was recently interviewed in BioStock ahead of BIO-Europe about his expectations and what Alzinova hopes to accomplish there. Read the interview (in Swedish) by following the link below! #bioeurope2023 #businessdevelopment #alzheimersresearch

🌟 A Remarkable Turn of Events: Ashington Innovation PLC's Bold Move Shapes Celixir's Future 🌟 🔬 The journey of U.K. cellular therapy trailblazer Celixir took an unexpected twist in July 2020 as the pandemic clouded the horizon of its cardio cell therapy clinical trial. A delay caused by the pandemic raised hopes of rekindling progress in the third quarter of that year. 🚀 Fast forward to today, and a game-changing development has unfolded – Ashington Innovation PLC, a dedicated force in innovation, orchestrated a reverse merger to acquire Celixir. A momentous transformation indeed! 🎉 💼 The numbers speak volumes: This acquisition, materialized through an all-share transaction, reflects a valuation of 135 million pounds sterling ($172.2 million). An impressive testament to the potential that lies within Celixir's pioneering work. 💰💎 🌱 Embracing this acquisition with open arms, Ashington Innovation envisions a bright future, further propelling the frontiers of drug development. And the story doesn't end there – an additional infusion of 3 million pounds ($3.8 million) is on the horizon, nurturing the growth of groundbreaking therapies. 💡 #innovationunleashed #medicaladvancements #CelixirAcquisition #ScienceAndProgress #innovation #unleashed #healthcare #lifesciences

#ikonisys, a company specializing in the early and accurate diagnosis of cancer through a unique and fully automated solution for medical testing laboratories, is pleased to announce the installation of the #Ikoniscope at Hospitex Lab. Hospitex Lab is the pathology anatomy laboratory located at the #hospitexinternational headquarters. This integration provides an ideal platform for the business operations of #IkonisysEurope, which will use the laboratory as a showroom, demonstration point, training center and center of excellence for #FISHtechnology. To this end, a series of promotional initiatives are planned with the participation of leading representatives of the medical and scientific community, first in Italy and then at the European level. Ikonoscope’s FISH technology will also be used internally by integrating it into #Urine24, Hospitex’s consumer oncology diagnostic product, further improving its sensitivity, reliability and efficiency. Finally, an offer to provide FISH technology as-a-service is being studied, targeting small private and public centers that do not have sufficient staff to handle a full installation, thus representing an additional source of revenue for the Group in the medium term. Mario Crovetto, CEO of Ikonisys, and Francesco Trisolini, CEO of Hospitex International, comment: "Early developments indicate that the integration of the two companies, which announced their merger plans in early December, is progressing at a record pace. These developments also underscore the significance of this transaction, as it aims to create substantial operational and business synergies."

💶 🚨 SciRhom has secured a EUR 63 Million Series A financing to accelerate iRhom2-targeting therapies in autoimmune diseases. ⬇ The financing enables us to shift gears and accelerate our novel and potentially groundbreaking therapeutic strategy toward clinical proof-of-concept and beyond to reach patients in need of better autoimmune treatments. SciRhom aims to push the boundaries in autoimmune medicine by addressing TACE/ADAM17, a master switch for various autoimmune disease-relevant signaling pathways, via iRhom2. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including HTGF | High-Tech Gründerfonds and the US-based PhiFund Ventures. We are excited to have attracted such a high-caliber international consortium of investors and appreciate our existing shareholders backing SciRhom in this crucial period of its development. In conjunction with this investment, we are excited to welcome Olivier Litzka, Peter Neubeck, Georgina Askeland, PhD, Dr. Fei Tian, and Varun Gupta to SciRhom’s Board of Directors and look forward to collaborating with them. Stay tuned and follow us here on LinkedIn to learn more about our novel approach as we progress toward initiation of a first clinical study in H2 2024. #venturecapital #financing #funding #fundingalert #SeriesA #iRhom2 #ADAM17 #TACE #autoimmune #IBD #RA #drugdiscovery #antibodyresearch #munichbiotech

Check out the livestream of the first session of TechKnow Invest Roadshow

Gene&Cell Therapy >> Co-founded by David Baker, Vilya rings in a permanent CEO; Allogene names Eric Schmidt's CFO successor: Cyrus Harmon → Ex-Olema Oncology chief Cyrus Harmon has resurfaced as CEO of Vilya, a Seattle-based macrocycle biotech from David Baker’s lab that raised a $50 million Series A last August. Harmon co-founded Olema in 2007 and he moved into the role of chief technology officer when Sean Bohen was hired as CEO three years ago. He then shifted to chief research officer until Olema restructured in March and laid off about 25% of its staff. CBO Kinney Horn joined Harmon on the chopping block, although Harmon is still on Olema’s board of directors. Former Bristol Myers Squibb exec Nick Meanwell and Arrakis chief innovation officer Jennifer Petter are part of Vilya’s scientific advisory board. Geoffrey Parker → Off-the-shelf cell therapy specialist Allogene has found a CFO. Former Goldman Sachs managing director Geoffrey Parker spent six years at Tricida and was elevated to COO, CFO and EVP in February 2021. Parker succeeds Eric Schmidt, who left Allogene this summer to become a biotech analyst for Cantor Fitzgerald and spoke with Lei Lei Wu as he prepared to dive in to his new gig. Allogene began the year by hiring R&D chief Zachary Roberts and has since picked up chief technical officer Tim Moore and general counsel Earl Douglas. John Tsai → Tom Anderson is out as CEO of Syncona-backed gene therapy maker SwanBio, but he’ll be a strategic advisor and keep his seat on a board that will now be chaired by ex-Novartis medical chief and current Syncona executive partner John Tsai. SwanBio has also recruited Topher Brooke as COO after he spent a year in the same role at Aytu BioPharma. Brooke is the former head of AstraZeneca’s diabetes business unit in North America and co-founded Rumpus Therapeutics, a pediatric disease biotech that was sold to Aytu in 2021. Tsai was just named CEO at another Syncona company, Forcefield Therapeutics, in late September. Richard Daly → AstraZeneca and Takeda alum Richard Daly will replace Patrick McEnany as CEO of Catalyst Pharmaceuticals on Jan. 1, while McEnany will remain chairman of the board. Daly last appeared in this space in January 2022, when he became president of CARsgen’s US subsidiary, CARsgen Therapeutics Corporation. He’s also been COO at BeyondSpring and a board member at Catalyst since 2015. Catalyst previously announced in July that McEnany would step down as chief executive. Michael Rossi → Michael Rossi will take over as president and CEO of Y-mAbs, and once Rossi starts running the biotech on Nov. 6, founder and interim chief Thomas Gad is slated to be vice chairman and CBO. Rossi was general manager of the US business for Novartis’ radiopharma company Advanced Accelerator Applications, and he’s also had a 12-year career with GE Healthcare. Y-mAbs has had a… #lucidquest #genetherapy #celltherapy

Qureight, a biotech firm founded by founded by Dr. Muhunthan Thillai and Alessandro Ruggiero, has successfully closed an $8.5 million Series A funding round. This round was led by prominent investors such as Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures and Michelle Tempest. Qureight's technology offers a revolutionary approach to managing and analyzing clinical trial data, which is crucial for enhancing drug development processes in complex diseases like lung and heart conditions. Qureight's platform uniquely integrates various types of medical data within a secure, cloud-based system that complies with multiple standards such as GDPR and NHS Digital. This integration facilitates more efficient clinical trials by allowing researchers to better manage and analyze critical data. This capability is crucial for advancing treatment options and improving survival rates for patients with severe illnesses, potentially leading to more effective and tailored therapies. Looking forward, Qureight plans to use this influx of capital to expand their AI-driven product portfolio and explore new therapeutic areas, including lung cancer.

Exciting times unfold in the German biotech scene, with familiar companies leading the charge. Rapid evolution fueled by robust investments, exceptional talent, and cutting-edge science catapults the industry onto the global stage. Germany's commitment to innovation has attracted significant investments, propelling it to the forefront of the international biotech arena. Recognizable names signify not only the strength of the German ecosystem but also its potential for global impact. This synergy of investment and talent has laid the foundation for a competitive and vibrant biotech landscape. From local recognition to global limelight, the success of German biotech is a testament to visionary investments and resilient minds. Cheers to the continued success and global influence of the German biotech industry! 🚀🌍🔍 #BiotechInnovation #GlobalImpact #GermanBiotechJourney

Michael A and Michael Z are true experts of the Swiss Life Sciences ecosystem!

Cranmore Executive Search played a pivotal role in Horizon's rapid and successful expansion into the European market. "I highly recommend Cranmore," says Chris Serafino. "My contact, Chris Sannwald is a very effective partner and helps me not only find the right candidate and fit, but also is patient with me as my needs grow or change." Read the full case study below on how Cranmore's tailored approach to executive search empowered Horizon Therapeutics' European expansion and fuelled their remarkable success! 📈✨ #SuccessStories #ExecutiveSearch #EuropeanExpansion #HorizonTherapeutics